Co-Diagnostics, Inc. Files 8-K on Sept 30, 2025
Ticker: CODX · Form: 8-K · Filed: Sep 30, 2025 · CIK: 1692415
| Field | Detail |
|---|---|
| Company | Co-Diagnostics, Inc. (CODX) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
Related Tickers: CDXC
TL;DR
CDXC filed an 8-K on 9/30/25 covering Reg FD and financials.
AI Summary
Co-Diagnostics, Inc. filed an 8-K on September 30, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Utah and its principal executive offices are located in Salt Lake City.
Why It Matters
This filing provides an official update from Co-Diagnostics, Inc. to the SEC, potentially containing material information for investors regarding financial status or regulatory disclosures.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports on significant events but doesn't inherently indicate new risks.
Key Numbers
- 1-38148 — SEC File Number (Identifies the specific SEC filing for Co-Diagnostics, Inc.)
- 46-2609363 — IRS Employer Identification Number (Tax identification number for Co-Diagnostics, Inc.)
Key Players & Entities
- Co-Diagnostics, Inc. (company) — Filer of the 8-K report
- September 30, 2025 (date) — Date of the earliest event reported and filing date
- Salt Lake City, Utah (location) — Location of principal executive offices
FAQ
What specific events are being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text.
What financial statements or exhibits are included with this 8-K?
The filing states 'Financial Statements and Exhibits' are included, but the content of these exhibits is not detailed in the provided text.
What is the primary business of Co-Diagnostics, Inc. based on the SIC code?
The Standard Industrial Classification (SIC) code 3841 indicates the company is in the 'Surgical & Medical Instruments & Apparatus' industry.
Where are Co-Diagnostics, Inc.'s principal executive offices located?
The principal executive offices are located at 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109.
What is the fiscal year end for Co-Diagnostics, Inc.?
The fiscal year end for Co-Diagnostics, Inc. is December 31 (1231).
Filing Stats: 390 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-09-30 09:32:23
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CODX The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 11KB
- 0001493152-25-016211.txt ( ) — 225KB
- codx-20250930.xsd (EX-101.SCH) — 3KB
- codx-20250930_lab.xml (EX-101.LAB) — 33KB
- codx-20250930_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2025 CO-DIAGNOSTICS, INC . (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification Number) 2401 S. Foothill Drive , Suite D , Salt Lake City , Utah 84109 (Address of principal executive offices) (801) 438-1036 (Issuer's telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CODX The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01. Regulation FD Disclosure. Exhibit 99.1 is incorporated by reference as if fully set forth herein. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No.: Description: 99.1 Press Release, dated September 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CO-DIAGNOSTICS, INC. Date: September 30, 2025 By: /s/ Brian Brown Name: Brian Brown Title: Chief Financial Officer (Principal Financial and Accounting Officer)